Khalid El Sayed
Professor
School Basic Pharm & Toxicol Sci
PHAR 324
318-342-1725
Khalid A El Sayed, PhD
Professor, School of Basic Pharmaceutical & Toxicological Sciences
Education
Ph D
1993, Pharmacy
Pharmacy, Mansoura University, Egypt
MS
1989, Masters of Science
Pharmacy, Mansoura University, Egypt
BS
1983, Pharmacy
Faculty of Pharmacy, Mansoura University, Egypt
Biographical Sketch
Professor El Sayed earned his Bachelor in Pharmacy, Master’s and Doctoral degrees in natural products chemistry/ pharmacognosy from Mansoura University, Egypt. His postdoctoral training was on marine natural products was at the University of Mississippi. Dr. El Sayed group is developing natural products for breast and other malignancies control. Dr. El Sayed group’s most important direction is the anti-breast cancer activity of olive phenolics, specifically S-(-)-oleocanthal through targeting the c-Met/HER2 receptor kinases and estrogen-α receptor. (-)-Oleocanthal recently validated by Dr. El Sayed group as an effective inhibitor of various breast cancer phenotypes locoregional recurrence. Other active projects in Dr. El Sayed laboratory include tobacco cembranoids/angiogenesis, lichen secondary metabolites and associated endophytes, PCSK9-LDLR small molecule inhibitors, Dr. El Sayed published more than 155 papers, 6 book chapters and awarded 13 patents. He has been funded by the National Cancer Institute (NCI), Louisiana Board of Regents, Louisiana Biomedical Research Foundation, Oleolive, Louisiana Biomedical Research Network, and several other foundations totaling more than two-million US dollars in extramural funding. Professor El Sayed served on several NCI study sections and is an editorial board member in Marine Drugs and Nutrients.
Research Interests
Nature has been and still is the single most important source of drugs and precursors. Over the past few decades, only one FDA-approved drug discovered from high-throughput screening of combinatorial chemistry libraries. Natural products-based drugs are still major entities source among the FDA-approved drugs. My research is merging traditional natural products, advanced medicinal chemistry-drug design and molecular pharmacology themes. Under natural products, my group has documented plant, marine invertebrates, and microbial discoveries. These included isolation of major and minor novel bioactive plant-marine-microbial ingredients, computer-aided semisynthetic optimizations of bioactive natural product scaffolds with occasional total and diverted synthesis, rational drug design-optimization, and molecular pharmacological-toxicological mechanistic studies. The exceptional diversity of natural products distinguish this field researcher as capable medicinal chemist, microbiologist, and pharmacologist. In addition to breast cancer-focused assays, we can actually utilize natural products into multiple therapeutic applications guided by the molecular target of interest. I consider myself a natural products-medicinal chemistry leader based on own group scientific productivity. My laboratory published more than 155 papers, 6 book chapters, filed, and awarded 14 patents on novel natural product entities and applications.
Recent Publications
Mohammed, Q., El Sayed, K. (2021). Comparative gene signature of (−)-oleocanthal formulation treatments in heterogeneous triple negative breast tumor models: Oncological therapeutic target insights. (pp. 1706). Basel: Nutrients/MDPI.
Tajmim, A., El Sayed, K. (2021). (-)-Oleocanthal nutraceuticals for Alzheimer’s disease amyloid pathology: Novel oral formulations, therapeutic, and molecular insights in 5xFAD transgenic mice model. Basel: Nutrients.
EL Sayed, K. (2020). HER2 Kinase-targeted breast cancer therapy: Design, synthesis, in vitro and in vivo evaluation of novel lapatinib congeners as selective and potent HER2 inhibitors with favorable metabolic stability. , 2020, 63, 24, 15906–15945. (pp. 15906–15945). Journal of Medicinal Chemistry.
El Sayed, K., Darakjian, L., Kaddoumi, A. (2021). Spontaneous in vitro and in vivo Interaction of (-)-Oleocanthal with Glycine in Biological Fluids: Novel Pharmacokinetic Markers. ACS Pharmacology. 2021, 4, 1, 179–192. (pp. 179–192). Washington DC/ACS: ACS Pharmacology & Translational Sciences.
El Sayed, K., Qusa, M., Meyer, S., Abdelwahed, K. (2020). ShThe olive oil lignan (+)-acetoxypinoresinol peripheral motor and neuronal protection against the tremorgenic mycotoxin penitrem A toxicity via STAT1 pathway. ACS Chemical Neuroscience. 2020, 11, 21, 3575–3589. (pp. 3575–3589). Washington DC/ACS: ACS Neuroscience.
El Sayed, K. (2021). S-(-)-Oleocanthal as a c-Met receptor tyrosine kinase inhibitor and its application to synergize targeted therapies and prevent breast cancer recurrence. In: Olive Oil in health and disease prevention, 2nd Edition, Academic Press. Olives and Olive Oil in Health and Disease Prevention. Chapter 57. https://doi.org/10.1016/B978-0-12-819528-4.00037-7. (pp. 681-691). Academic Press.
Ayoub, N., El Sayed, K. (2017). The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. Eur J Pharmacol, 2017, 810, 100–111. (pp. 100–111). London: European Journal of Pharmacology.
Soumaya, S., El Sayed, K. (2018). Bioguided discovery of the 131-oxophorbine protopheophorbide A as a novel mesenchymal-epithelial transition factor receptor inhibitory lead from the Tunisian Ziziphus lotus for the control of breast malignancies. PMID: 29978911 (pp. 1507-1524). Molecular Carcinogenesis.
Goda, A., El Sayed, K. (2018). The Maxi-K (BK) channel antagonist penitrem A as a novel breast cancer targeted therapeutic (pp. 157). MDPI: Marine Drugs.
Siddique, A. B., El Sayed, K. (2019). (−)-Oleocanthal combined with lapatinib treatment synergized against HER-2 positive breast cancer in vitro and in vivo. PMID: 30781364 (pp. 412). MDPI: Nutrients.
Siddique, A. B., El Sayed, K. (2019). Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity. (pp. e0214798). PlosOne.
Siddique, A. B., Meyer, S., El Sayed, K., Hill, R. (2019). S-(-)-Oleocanthal prevents breast cancer locoregional recurrence after primary tumor surgical excision and neoadjuvant targeted therapy in orthotopic nude mouse models. PMID: 31072015. (pp. 637). Basel: Cancers (Basel)/MDPI.
Qusa, M., El Sayed, K. (2019). Novel olive oil Phenolic (-)-oleocanthal (+)-xylitol-based solid dispersion formulations with potent oral anti-breast cancer activities. PMID 31394181 (pp. 118596). Elsevier: International Journal of Pharmaceutics.
Abdelwahed, K., Jois, S., El Sayed, K. (2020). Pseurotin A as a novel suppressor for the hormone dependent breast cancer progression and locoregional recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor. (pp. 104847). Rome/Elsevier: Pharmacological Research.
Kamal, M., Nazzal, S., El Sayed, K. (2020). Development and Characterization of Curcumin-Loaded Solid Self-Emulsifying Drug Delivery System (SEDDS) by Spray Drying Using Soluplus® as Solid Carrier (pp. 137-145). Elsevier: Powder Technology.
Elmaidomy, A., El Sayed, K. (2020). New acylated rhamnopyranoses from Premna odorata and their triple negative breast cancer suppressive activity (pp. 10584). RSC Adv.
Kaddoumi, A., El Sayed, K. (2020). Comments on the published article entitled: Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats published in Pharmaceutics. PMID:32751928 (pp. 720). Basel: Pharmaceutics-MDPI.
Tajmim, A., El Sayed, K., Siddique, A. B. (2019). Optimization of taste-masked (–)-oleocanthal effervescent formulation with potent breast cancer progression and recurrence suppressive activities. (pp. 515). Basel: Pharmaceutics- MDPI.
Elkhalifa, D., El sayed, K. (2020). EDesign, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer. (pp. 111954). European Journal of Medicinal Chemistry/Elsevier.
Siddique, A. B., Meyer, S., El Sayed, K. (2020). Safety evaluations of single dose of the olive secoiridoid S-(-)-oleocanthal in Swiss albino mice. (pp. 314). Basel: Nutrients/MDPI.
Siddique, A. B., Meyer, S., Jois, S., El Sayed, K. (2020). (−)-Oleocanthal as a dual c-MET-COX2 inhibitor for the control of lung cancer. (pp. 1749). Basel: Nutrients/MDPI.
Sallam AA, Mohyeldin MM, Foudah AI, Akl MR, Nazzal SM, Meyer SA, Yong-Yu Liu YY, El Sayed KA. Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling. 2014. Organic & Biomolecular Chemistry 12, 5295–5303.
Akl MR, Ayoub NM, Ebrahim HY, Foudah AI, Mohyeldin MM, Orabi KY, El Sayed KA. Araguspongine C induces autophagic death in breast cancer cells through suppression of c-Met and HER2 receptor tyrosine kinase signaling. 2015. Marine Drugs, 13, 288-311.
Martins AH, Hu J, Xu Z, Mu C, Alvarez P, Ford BD, El Sayed K, Eterovic VA, Ferchmin PA, Hao J. Neuroprotective activity of (1S,2E,4R,6R,-7E,11E)-2,7,11-cembratriene-4,6-diol (4R) in vitro and in vivo in rodent models of brain ischemia. 2015. Neuroscience, 291, 250-259.
Zhang Y, Zhang YK, Wang YJ, Vispute SG, Jain S, Li J, Chen Y, Youssef DTA, EI Sayed KA, Chen ZS. Esters of the marine-derived triterpene sipholenol A reverse P-gp-mediated drug resistance. 2015. Marine Drugs, 13, 2267-2286.
Khanfar MA, Bardaweel SK, Akl MR, EI Sayed KA. Olive oil-derived oleocanthal as potent inhibitor of mammalian target of rapamycin: Biological evaluation and molecular modeling studies. 2015. Phytotherapy Research, 29(11), 1776-1782.
Gray AL, Coleman DT, Castorea RF, Mohyeldin MM, El Sayed KA, Cardelli JA. Isothiocyanatostilbenes as novel c-Met inhibitors. 2015. Oncotarget, 6(38), 41180-41193.
Gray AL, Coleman DT, Castorea RF, Mohyeldin MM, El Sayed KA, Cardelli JA. Isothiocyanatostilbenes as novel c-Met inhibitors. 2015. Oncotarget, 6(38), 41180-41193.
Abu-Fayyad A, Behery F, Sallam A, Alqahtani S, Ebrahim H, El Sayed KA, Kaddoumi A, Sylvester PW, Carroll JL, Cardelli JA, Nazzal S. PEGylated γ-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability. 2015, Eur J Pharm Biopharm, 96, 185-195.
Qosa H, Batarseh Y, Mohyeldin M, El Sayed KA, Keller J, Kaddoumi A. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. ACS Chemical Neuroscience. 2015. 6(11), 1849-1859.
Mady MS, Mohyeldin MM, Ebrahim HY, Elsayed HE, Houssen WE, Haggag EG, Soliman RF, El Sayed KA. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion. 2016. Bioorg Med Chem. 24, 113-122.
Ebrahim HY, El Sayed KA. Antiangiogenic marine natural product scaffolds. 2016. Marine Drugs, 14, 57; doi:10.3390/md14030057.
Mohyeldin MM, Busnena BA, Akl MR, Dragoi AM, Cardelli JA, El Sayed KA. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. 2016. Eur J Med Chem. 118, 299-315.
Mohyeldin MM, Akl MR, Dragoi AM, Cardelli JA, El Sayed KA. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. 2016. Oncotarget, 7, 32247-32273. PMID: 27086914.
Ebrahim HY, Elsayed HE, Mohyeldin MM, Akl MR, Bhattacharjee J, Egbert S, El Sayed KA. Norstictic acid inhibits breast cancer cell proliferation, migration, invasion, and in vivo invasive growth through targeting c-Met. 2016. Phytotherapy Research, 30, 557–566.
Mudit M, El Sayed KA. Cancer control potential of marine natural product scaffolds through inhibition of tumor cellular migration and invasion. Drug Discovery Today, 2016, 21, 1745-1760.
Goda A, Naguib K, Mohamed M, Amra H, Nada S, Abdel-Ghaffar AR, Gissendanner CR, El Sayed KA Astaxanthin and docosahexaenoic acid reverse the toxicity of the Maxi-K (BK) channel antagonist mycotoxin penitrem A. Marine Drugs. 2016, 14, 208; doi:10.3390/md14110208.
Ebrahim HY, Moheyldin MM, Hailat MM, El Sayed KA. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-Dependent breast malignancies. Bioorg Med Chem, 2016, 24, 5748-5761. PMID: 27681240.
Mohyeldin, M., El Sayed, K. (2017). The marine-derived pachycladin diterpenoids as novel wild and mutant EGFR inhibitors. PMID: 27940262 (pp. 51-68). Biochemical Pharmacology/Elsevier.
Palem JR, Mudit M, Hsia SCV, El Sayed KA. Discovery and preliminary structure-activity relationship of the marine natural products manzamines as herpes simplex virus type-1 inhibitors. Zeitschrift für Naturforschung C, 2017, 72(1-2), 49-54. PMID: 27447204.
Ebrahim HY, Akl M, Elsayed H, Hill, R, El Sayed KA. Usnic acid benzylidene analogs as potent mTOR inhibitors for the control of breast malignancies. J Nat Prod, 2017, 80, 932−952. PMID: 28245124.
Hailat M, Ebrahim HY, Siddique A, Goda A, El Sayed KA. (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitor for the control of triple negative breast malignancies. Bioorg Med. Chem. 2017, 25, 3911-3921.
Elsayed HE, Ebrahim HY, Haggag EG, Kamal AM, El Sayed KA. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies. Bioorg Med Chem. 2017, 25, 6297–6312.
Batarseh YS, Mohamed LA, Al Rihani SB, Mousa YM, Siddique A, El Sayed KA, Kaddoumi A. Oleocanthal ameliorates amyloid-β oligomers toxicity on astrocytes and neuronal cells: In-vitro studies. Neuroscience 2017, 352, 204–215. PMID: 28392295.
Elsayed HE, Ebrahim HE, Mohyeldin MM, Siddique A, Haggag EG, Kamal AM, El Sayed KA. Rutin as a novel c-Met inhibitory lead for the control of breast malignancies. Nutrition & Cancer, 2017, 69, 1256-1271. PMID: 29083228.
Mady MS, Houssen W, Abdou R, Haggag EG, El Sayed KA. Bioactive secondary metabolites isolated from endophytic fungus Penicillium citrinium associated with olive tree fruit. Journal of Advanced Pharmacy Research, 2017, 1, 160-170.
Acylated iridoids and rhamnopyranoses from Premna odorata (Lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer. Elmaidomy AH, Mohyeldin MM, Ibrahim MM, Hassan HM, Amin E, Rateb ME, Hetta MH, El Sayed KA. Phytotherapy Research, 2017, 31, 1546–1556. PMID: 28809058.
Ayoub NM, Siddique AB, Ebrahim HY, Mohyeldin MM, El Sayed KA. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. Eur J Pharmacol, 2017, 810, 100–111.
Sawant, S. S., Sylvester, P. W., El Sayed, K. A. Bioactive rearranged and halogenated semisynthetic derivatives of the marine natural product sarcophine. (pp. 2017-2023). OHIO: Journal of Natural Products/American Chemical Society.
El Sayed, K. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors (pp. 4928-4934). Bioorganic Medicinal Chemistry-Elsevier.
Alaa, A. H., Hisham, Q., Belnaser, B., El Sayed, K., Khalil, A. (2013). Olive Oil-Derived Oleocanthal Enhances β-Amyloid Clearance as a Potential Neuroprotective Mechanism against Alzheimerâs Disease: In-vitro and In-vivo Studies. ACS Chem Neurosci.
El Sayed, K., Chelette, C. T. (2014). Design and Evaluation of Laboratory Exercises to Teach Clinically-Relevant Chemistry of Antibiotics Using Chemical and Spectural Experimental Approaches. Columbia, SC: American Journal of Pharmaceutical Education.
El Sayed, K. (2013). Olive secoiridoids and semisynthetic bioisosteres for the control of metastatic breast cancer (pp. 2117-21127). New York: Elsevier-Bioorganic Medicinal Chemistry.
El Sayed, K. (2013). Optimization of the marine triterpene sipholenols as inhibitors of breast cancer migration and invasion (pp. 497-510). Germany: ChemMedChem/Wiley.
El Sayed, K. (2013). The Veratrum alkaloids jervine, veratramine, and their analogues as prostate cancer migration and proliferation inhibitors. (pp. 4775-4786). Medicinal Chemistry Communication-RCS.
El Sayed, K., Sylvester, P. W. (2013). Discovery and optimization of tocotrienol electrophilic substitution products as antiproliferative and antimigratory leads (pp. 329-341). European Journal of Medicinal Chemistry-Elsevier.
El Sayed, K. Anticancer 3-methyl-2,5-diarylpyrimido[4,5-c]quinolin-1(2H)-ones: Structure-activity relationship of methoxy substitution (pp. DOI 10.1007/s00044-012-0428-9). Medicinal Chemistry Research.
El Sayed, K. (2012). Current status on marine natural products with reversal effect on cancer multidrug resistance. Marine Drugs.
El Sayed, K. (2012). Subereamolline A as a potent breast cancer migration, invasion and proliferation inhibitor and bioactive dibrominated alkaloids from the Red Sea sponge Pseudoceratina arabica (pp. 2492-2508). Marine Drugs.
El Sayed, K. (2012). Mannich- and Lederer-Manasse-based analogues of the natural product S (+)-curcuphenol as cancer proliferation and migration inhibitors (pp. 1309-1315). Medicinal Chemistry Communication-RCS.
El Sayed, K. (2011). Design of semisynthetic analogues and 3D-QSAR study of eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors (pp. 1122-1130). European Journal of Medicinal Chemistry-Elsevier.
Alaa, A. H., Hisham, Q., Nick, O. D., Jessica, A., Sylvester, P. W., El Sayed, K., Khalil, A. (2011). Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products (pp. 2765-72). Food Chem Toxicol.
El Sayed, K. (2011). Optimization of phenylmethylene hydantoins as prostate cancer migration inhibitors: SAR-directed design, synthesis, and pharmacophore modeling. (pp. 1470-1485). Chemistry & Biodiversity.
Ramasaham, S., El Sayed, K., Meyer, S. Effects of chemically characterized fractions from aerial parts of Echinacea purpurea and angustifolia on myelopoiesis in rats. Planta Medica.
El Sayed, K. (2011). Antimicrobial, antioxidant, and antimutagenic activities of selected marine natural products and tobacco cembranoids (pp. 167-179). Drug and Chemical Toxicology.
El Sayed, K., Shah, G. (2011). Discovery, design, and development of anti-invasive natural product leads. Methods in Molecular Biology Protocols- Drug Design and Discovery (pp. 55-76).
Hill, R. A., Khanfar, M. A., Khalil, A., El Sayed, K. (2010). Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening (pp. 8534-8545). ACS Journals: Journal of Medicinal Chemistry.
El Sayed, K. (2010). Phenylmethylene hydantoins as prostate cancer invasion and migration inhibitors. CoMFA approach and QSAR analysis (pp. 5397-5405). New York: European Journal of Medicinal Chemistry, Elsevier.
Behery, F., Elnagar, A., Wali, V., Abouasal, B., Akl, M., Khalil, A., Sylvester, P. W., El Sayed, K. (2010). Redox-Silent Tocotrienol Esters as Breast Cancer Proliferation and Migration Inhibitors (pp. 8066-8075). New York: Bioorganic & Medicinal Chemistry, Elsevier.
Sallam, A., Ramasahayam, S., Meyer, S., El Sayed, K. (2010). Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration (pp. 7446â7457). New York: Elsevier.
Hassan, H., Khanfar, M., Elnagar, A., Mohamed, R., Yousef, D., shalaa, L., Hifnway, M., El Sayed, K. (2010). Pachycladins A-E: Prostate Cancer Invasion and Migration Inhibitory Eunicellin-Based Diterpenoids from the Red Sea Soft Coral Cladiella pachyclados (pp. 848â853). Washington, DC: Journal of Natural Products/American Chemical Society.
Baraka, H., Khanfar, M., Williams, J., El Giar, E., Shah, G., El Sayed, K. Bioactive Natural, Biocatalytic, and Semisynthetic Tobacco Cembranoids. Planta Medica.
Mhammad, K. A., Youssef, D. T., El Sayed, K. (2010). Rationale design of semisynthetic latrunculin analogs as inhibitors for metastatic breast cancer, preliminary structure-activity relationship, and molecular modeling studies. (pp. 274-285). John Wiley: ChemMedChem.
Abdelbar, F., El Sayed, K., Sylvester, P. W., Raisch, K., Zaghloul, A., Badria, F., Mohammad, K., Elnagar, A. (2010). Design and pharmacophore modeling of microtubule-disrupting biaryl methyl eugenol analogs as breast cancer invasion inhibitors (pp. 496â507). Bioorganic Medicinal Chemistry/Elsevier.
Elnagar, A., Sylvester, P. W., Wali, V., El Sayed, K. (2010). Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. (pp. 755-768). New York: Bioorganic & Medicinal Chemistry-.
Mhammad, K. A., Youssef, D. T., El Sayed, K. (2010). Rationale design of semisynthetic latrunculin analogs as inhibitors for metastatic breast cancer, preliminary structure-activity relationship, and molecular modeling studies. (pp. 274-285). John Wiley: ChemMedChem.
El Sayed, K., Elnagar, A., Wali, V., Sylvester, P. W. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. New York: Bioorganic & Medicinal Chemistry-.
Khanfar, M. A., Abuasal, B., Mudit, M., Khalil, A., El Sayed, K. (2009). The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. (pp. 6032-6039). Bioorganic & medicinal chemistry.
El Sayed, K., Jain, S., Abraham, I., Carvalho, P., Kuang, Y. H., Youssef, D. T., Avery, M., Chen, Z. S. (2009). The marine sipholane terpenoids: Novel structures, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. (pp. 1291-1298). Washington, DC/American Chemical Society: Journal of Natural Products.
Mudit, M., Khanfar, M., Muralidharan, A., Thomas, S., Shah, G., El Sayed, K. (2009). Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. (pp. 1531-1538). Washington DC, Elsevier: Bioorganic & Medicinal Chemistry.
Shah, G., Muralidharan, A., Thomas, S., Gokulgandhi, M., Mudit, M., Khanfar, M., El Sayed, K. (2009). Identification of a small molecule(s) class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis (pp. 509-522). Washington DC/American Association for Cancer Research: Molecular Cancer Therapeutics.
Abdel Bar, F. A., Khanfar, M. A., H, L., Raisch, K. P., Sylvester, P. W., Zaghloul, A. M., Badria, F. A., El Sayed, K. (2009). Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors (pp. 1643-1650). Washington DC/American Chemical Society: Journal of Natural Products.
El Sayed, K. (2008). Biocatalytic and semisynthetic optimization of the anti-invasive tobacco (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol. (pp. 2886-2893). Elsevier Sciences: Bioorganic and Medicinal Chemistry.
El Sayed, K. (2008). Latrunculin A and Its C-17-O-Carbamates Inhibit Prostate Cancer Invasion and Breast Cancer HIF-1 Activation. (pp. 396-402). American Chemical Society: Journal of Natural Products.
El Sayed, K. (2008). Semisynthetic and biocatalytic optimization of the anticancer tobacco (1S,2E,4S,6R,7E,11E)-2,7,11-cembratriene-4,6-diol. (pp. 117-122). Washington DC, American Chemical Society: Journal of Natural Products.
El Sayed, K. A., Youssef, D. T., Marchetti, D. Bioactive natural and semisynthetic latrunculins. Journal of Natural Products. OHIO: Journal of Natural Products.
El Sayed, K. A. (2005). Natural products as angiogenesis modulators. (pp. 971-993). Bentham: Mini Reviews in Medicinal Chemistry.
El Sayed, K. A. (2000). Studies in Natural Product Chemistry: Natural products as antiviral agents (pp. 473-572). Amsterdam: Elsevier Science Publishers.
Research Grants
El Sayed, K. (Principal), "Oleocanthal functional food products for breast cancer recurrence control." (Funded), Sponsored By National Cancer Institute - R41CA247025, External to The University of Louisiana at Monroe, $240,000. (June 01 2020 - May 31 2021).
El Sayed, K. (Principal), Kaddoumi, A. (Co-Principal), "BoR-Indstry Tie Research Subprogram" (Funded), Sponsored By Louisiana Board of Regents, External to The University of Louisiana at Monroe, $270,000. (June 01 2017 - June 30 2020).
El Sayed, K. (Principal), Jois, S. (Co-Principal), "Novel PCSK9-LDLR interaction natural product inhibitors for neurological disorders" (Funded), Sponsored By Biomedical Research Foundation, External to The University of Louisiana at Monroe, $50,000. (February 01 2018 - January 31 2019).
Patents
El Sayed, K. (2021). Oleocanthal isolation and cancer treatment. US Patent No. 10,945,983.
Awards & Honors
May 2016 Thomas Lemke Outstanding Student Poster Presentation Award to A. Siddique .
August 2014 University of Louisiana at Monroe Excellence in Research Foundation Award.
February 2013 Open Innovation Drug Discovery Program: Outstanding Contribution to Continuous Compound Submission Award.
May 2012 The Robert A Magarian Outstanding Student Podium Presentation Award.
July 2011 AAPS Graduate Student Symposium-Drug Design & Discovery.
May 2011 Voted Professor of the Year by the 2013 class.
July 2010 AAPS Graduate Student Award.
March 2010 The Lynne Brady Travel Award to Student.
March 2010 The Kilmer Prize Award to Student.
July 2009 AAPS Graduate Student Award.
July 2009 AAPS Graduate Student Award.
March 2008 Am Society Pharmacognosy Travel Award.
April 2007 The Kilmer Prize Award Mentor.
May 2006 Outstanding Professor Award.
April 2006 AFPE Mentor.
April 2005 The Kilmer Prize Award Mentor.
April 2005 AFPE Mentor.
Courses Taught
PHAR 4010Medicinal Chemistry III, 1 course(s)
PHAR 4018Chemotherapeutic Agts, 4 course(s)
PHAR 4021Herbal Remedies, 4 course(s)
PHAR 5066ADVANCED MEDICINAL ANALYSIS, 6 course(s)
PHAR 5068ADV MEDICINAL ANALYSIS LAB, 6 course(s)
PHAR 5099THESIS, 2 course(s)
PHAR 5139MOLEC THEOR FNDTNS, 5 course(s)
PHRD 4002PRINCIPLES OF DRUG ACTION I, 7 course(s)
PHRD 4008PHARMACEUTICS I, 5 course(s)
PHRD 4027PRINCIPLES OF DRUG ACTION II, 7 course(s)
PHRD 4064THERAPEUTICS I, 1 course(s)
PHRD 4072THERAPEUTICS II, 6 course(s)
PHRD 4074ENDOCRINE MODULE, 5 course(s)
PHRD 4081INFECTIOUS DISEASES MODULE, 8 course(s)
PHRD 4085THERAPEUTICS III, 6 course(s)
PHRD 4093THERAPEUTICS IV, 1 course(s)
PHRD 5010Cardiovascular Module, 1 course(s)
PHRD 5014THERAPEUTICS V, 5 course(s)
PHRD 5022THERAPEUTICS VI, 1 course(s)
PHRD 5031RESPIRATORY MODULE, 4 course(s)
PHRD 5039THERAPEUTICS VII, 1 course(s)
PHRD 5047THERAPEUTICS VIII, 1 course(s)
PHRD 5053HERBAL REMEDIES, 8 course(s)
PHRD 5064PROBLEMS, 21 course(s)